Drug intelligence / Profile preview

Weiwei

Development stage: Preclinical
Lead developer: Guangzhou University of Chinese Medicine
Administration: Oral

Overview

Weiwei granule is a traditional Chinese medicine currently undergoing investigation for its therapeutic potential in gastric intestinal metaplasia. Its mechanism of action involves intervening with the NOD1/CDX2 pathway, a process that is mediated by OLFM4. The drug is being developed by institutions such as Guangzhou University of Traditional Chinese Medicine and Shenzhen TCM Hospital.

Targets

CDX2 (Caudal type homeobox 2)NOD1 (Nucleotide-binding oligomerization domain-containing protein 1)

Beyond the preview

Go deeper on Weiwei.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Weiwei.

Explore the full profile